CTOs on the Move

Frederick Memorial Healthcare System

www.fmh.org

 
Frederick Memorial Healthcare System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Frederick Memorial Healthcare System is based in Frederick, MD. You can find more information on Frederick Memorial Healthcare System at www.fmh.org
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.fmh.org
  • 400 W 7th St
    Frederick, MD USA 21701
  • Phone: 240.566.3300

Executives

Name Title Contact Details

Similar Companies

Sullivan Arc Inc

Sullivan Arc Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Monticello, NY. To find more information about Sullivan Arc Inc, please visit www.sullivanarc.org

Mission Healthcare

Mission Healthcare is a provider of home-based healthcare and hospice services in Southern California. They offer a wide range of professional healthcare and support services provided in the home, including home health, home care, and hospice.

QuVa Pharma, Inc

QuVa Pharma, Inc. is a newly-formed national platform for sterile compounding pharmacy services led by two experienced industry executives that has received a majority equity commitment from Bain Capital Private Equity to support the company’s creation and expansion plans. As part of its formation, QuVa Pharma has acquired the assets of the compounding services division of a company leader in the field of parenteral and management services, including its state-of-the-art 503B manufacturing facility in Sugar Land, Texas.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.

AAIPharma Services Corp.

aaiPharma Inc. (aaiPharma) is a science-based pharmaceutical company offering pharmaceutical development capabilities primarily in the United States and Europe.